Founder & CEO, Bradley Burnam, to Ring NASDAQ “Closing Bell” at 4:00 PM ETWESTLAKE VILLAGE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces that its common stock is scheduled to commence trading today, October 8, 2025, on the Nasdaq Capital Market under ticker symbol “TTRX.” The Company’s registration statement on Form S-1 was declared effectiv ...